Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Pulse Biosciences (PLSE) Equity Average (2020 - 2025)

Historic Equity Average for Pulse Biosciences (PLSE) over the last 6 years, with Q3 2025 value amounting to $98.6 million.

  • Pulse Biosciences' Equity Average rose 8584.45% to $98.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $98.6 million, marking a year-over-year increase of 8584.45%. This contributed to the annual value of $79.6 million for FY2024, which is 27809.18% up from last year.
  • Pulse Biosciences' Equity Average amounted to $98.6 million in Q3 2025, which was up 8584.45% from $111.5 million recorded in Q2 2025.
  • Pulse Biosciences' 5-year Equity Average high stood at $116.7 million for Q1 2025, and its period low was -$6.5 million during Q1 2023.
  • In the last 5 years, Pulse Biosciences' Equity Average had a median value of $40.3 million in 2024 and averaged $47.6 million.
  • Within the past 5 years, the most significant YoY rise in Pulse Biosciences' Equity Average was 234874.4% (2023), while the steepest drop was 11982.32% (2023).
  • Over the past 5 years, Pulse Biosciences' Equity Average (Quarter) stood at $45.9 million in 2021, then plummeted by 95.7% to $2.0 million in 2022, then surged by 2348.74% to $48.3 million in 2023, then soared by 101.02% to $97.0 million in 2024, then rose by 1.64% to $98.6 million in 2025.
  • Its Equity Average was $98.6 million in Q3 2025, compared to $111.5 million in Q2 2025 and $116.7 million in Q1 2025.